Be Bio raises $82M to fund work on B cell therapy in hemophilia B
Be Bio’s $82 million round announced Tuesday will help the Cambridge, MA-based biotech fund work for two of its drugs in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
